> Cobenfy, set to launch in October, will have a list price that would cost about $22,500 a year. The influential Institute for Clinical and Economic Review this year estimated that a price in line with expected clinical benefits to patients should be in the range of $16,000 to $20,000 a year. Bristol Myers Squibb executives say most eligible patients are covered by Medicare or Medicaid and wouldn’t pay the list price.
You're being downvoted for using an easily google-able factoid incorrectly because you're pattern matching on "high drug prices"
What happened was Martin Shekreli purchased patents for existing life-saving drugs and raised the price for them from $1.50 to $30 to cover the cost of the purchasing the patents themselves.
The company paid $14b for the research to bring this drug to market. Like all Americans — and all citizens of the world, apparently — I agree that drug prices in the US are too high, but shouldn't they be allowed to at least recoup that investment?
How can we expect companies like this to continue researching such drugs if not? Especially when, more often than not, the research leads to a dead end or failed trials, and they can't even bring the drug to market?
Legends say that Shkreli was actually trying to rip off insurance companies and left individuals alone, even going as far as to give it away for $1 to people without insurance, but I'm not sure.
